ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Schering adds imaging agents

July 24, 2006 | APPEARED IN VOLUME 84, ISSUE 30

Schering and Avid Radiopharmaceuticals will codevelop diagnostic imaging agents for Alzheimer's disease. Avid makes compounds that bind to the amyloid plaques in the brain that are believed to cause Alzheimer's. The deal gives Schering the exclusive rights to develop and commercialize those compounds for use with positron emission tomography scanning technology. There is no clinical method to definitively diagnose Alzheimer's. Separately, Schering has elected to return to Epix Pharmaceuticals the full rights to Epix's fibrin-binding imaging agent EP-2104R, which has completed Phase IIa studies of its potential to detect blood clots through magnetic resonance imaging.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment